Literature DB >> 15255225

Regional variation and clinical indicators of antipsychotic use in residential treatment: a four-state comparison.

Purva H Rawal1, John S Lyons, James C MacIntyre, John C Hunter.   

Abstract

The last decade saw an increase in psychotropic use with pediatric populations. Antipsychotic prescriptions are used frequently in residential treatment settings, with many youth receiving antipsychotics for off-label indications. Residential treatment data from 4 states were examined to determine if regional variation exists in off-label prescription and what clinicalfactors predict use. The study used clinical and pharmacological data collected via retrospective chart reviews (N = 732). The Child and Adolescent Needs and Strengths Assessment-Mental Health Version was used to measure symptom and risk severity. Of youth receiving antipsychotics, 42.9% had no history of or current psychosis. Statistical analyses resulted in significant regional variation in use across states and yielded attention deficit/impulsivity, physical aggression, elopement, sexually abusive behavior, and criminal behavior as factors associated with antipsychotic prescription in nonpsychotic youth. Antipsychotic prescription is inconsistent across states. Off-label prescription is frequent and likelihood of use increases with behavior problems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15255225     DOI: 10.1007/BF02287380

Source DB:  PubMed          Journal:  J Behav Health Serv Res        ISSN: 1094-3412            Impact factor:   1.505


  21 in total

Review 1.  Antipsychotic medications for children and adolescents.

Authors:  B L Gracious; R L Findling
Journal:  Pediatr Ann       Date:  2001-03       Impact factor: 1.132

2.  Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.

Authors:  H A Pincus; T L Tanielian; S C Marcus; M Olfson; D A Zarin; J Thompson; J Magno Zito
Journal:  JAMA       Date:  1998-02-18       Impact factor: 56.272

3.  Medication management of stimulants in pediatric practice settings: a national perspective.

Authors:  K Hoagwood; P S Jensen; M Feil; B Vitiello; V S Bhatara
Journal:  J Dev Behav Pediatr       Date:  2000-10       Impact factor: 2.225

4.  A double-blind pilot study of risperidone in the treatment of conduct disorder.

Authors:  R L Findling; N K McNamara; L A Branicky; M D Schluchter; E Lemon; J L Blumer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-04       Impact factor: 8.829

5.  Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.

Authors:  Richard P Malone; Greg Maislin; Muniya S Choudhury; Cynthia Gifford; Mary Anne Delaney
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-02       Impact factor: 8.829

Review 6.  Pediatric psychopharmacology and the interaction between drugs and the developing brain.

Authors:  B Vitiello
Journal:  Can J Psychiatry       Date:  1998-08       Impact factor: 4.356

7.  Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

Authors:  Atilla Turgay; Carin Binder; Richard Snyder; Sandra Fisman
Journal:  Pediatrics       Date:  2002-09       Impact factor: 7.124

Review 8.  The antipsychotics. A pediatric perspective.

Authors:  R L Findling; S C Schulz; M D Reed; J L Blumer
Journal:  Pediatr Clin North Am       Date:  1998-10       Impact factor: 3.278

Review 9.  Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

Authors:  Elizabeth Pappadopulos; James C Macintyre Ii; M Lynn Crismon; Robert L Findling; Richard P Malone; Albert Derivan; Nina Schooler; Lin Sikich; Laurence Greenhill; Sarah B Schur; Chip J Felton; Harvey Kranzler; David M Rube; Jeffrey Sverd; Molly Finnerty; Scott Ketner; Sonja E Siennick; Peter S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-02       Impact factor: 8.829

10.  Risperidone for young children with mood disorders and aggressive behavior.

Authors:  H A Schreier
Journal:  J Child Adolesc Psychopharmacol       Date:  1998       Impact factor: 2.576

View more
  7 in total

1.  State Investments in Psychiatric Innovation: Investigating Unmeasured State Factors.

Authors:  Marisa Elena Domino; Christopher Alan Beadles
Journal:  Health Serv Outcomes Res Methodol       Date:  2014-06-01

Review 2.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

3.  Patterns of Antipsychotic Prescribing by Physicians to Young Children.

Authors:  Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2016-07-15       Impact factor: 3.084

4.  Antipsychotic treatment patterns and aggressive behavior among adolescents in residential facilities.

Authors:  Leslie Miller; Mark A Riddle; David Pruitt; Al Zachik; Susan dosReis
Journal:  J Behav Health Serv Res       Date:  2013-01       Impact factor: 1.505

Review 5.  A review of geographic variation and Geographic Information Systems (GIS) applications in prescription drug use research.

Authors:  Victoria Wangia; Theresa I Shireman
Journal:  Res Social Adm Pharm       Date:  2013-01-18

6.  Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health.

Authors:  Brendan Saloner; Meredith Matone; Amanda R Kreider; M Samer Budeir; Dorothy Miller; Yuan-Shung Huang; Ramesh Raghavan; Benjamin French; David Rubin
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

7.  Psychotropic medications prescribing patterns for children and adolescents in New York's public mental health system.

Authors:  John S Lyons; James C MacIntyre; Michael E Lee; Sharon Carpinello; Michael P Zuber; Marcia L Fazio
Journal:  Community Ment Health J       Date:  2004-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.